Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease ; volume:6 ; number:1 ; day:14 ; month:5 ; year:2018 ; pages:1-7 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (14.5.2018), 1-7, 12.2018
- Creator
-
Boyiadzis, Michael M.
- Contributor
-
Kirkwood, John M.
Marshall, John L.
Pritchard, Colin C.
Azad, Nilofer S.
Gulley, James L.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0342-x
- URN
-
urn:nbn:de:101:1-2018071516144279098663
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Boyiadzis, Michael M.
- Kirkwood, John M.
- Marshall, John L.
- Pritchard, Colin C.
- Azad, Nilofer S.
- Gulley, James L.
- SpringerLink (Online service)
Other Objects (12)
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Pembrolizumab
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Pembrolizumab
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Pembrolizumab
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs